Characteristics of a widespread community cluster of H275Y oseltamivir-resistant a(H1N1)pdm09 influenza in Australia

Journal of Infectious Diseases

Volumn 206, Issue 2, 2012, Pages 148-157

  Hurt, A C ^a   Hardie, K ^b   Wilson, N J ^c   Deng, Y M ^a   Osbourn, M ^b   Leang, S K ^a   Lee, R T C ^d   Iannello, P ^a   Gehrig, N ^c   Shaw, R ^a   Wark, P ^e   Caldwell, N ^a   Givney, R C ^c   Xue, L ^a   Maurer Stroh, S ^d,f,g   Dwyer, D E ^h   Wang, B ^h   Smith, D W ^i,j   Levy, A ⁱ   Booy, R ^h,k,l   Dixit, R ^k   Merritt, T ^b   Kelso, A ^a   Dalton, C ^b   Durrheim, D ^b   Barr, I G ^a   more..

^a WHO COLLABORATING CENTRE FOR REFERENCE AND RESEARCH ON INFLUENZA   (Australia)

^b HUNTER NEW ENGLAND POPULATION HEALTH   (Australia)

^c JOHN HUNTER HOSPITAL   (Australia)

^d BIOINFORMATICS INSTITUTE   (Singapore)

^e UNIVERSITY OF NEWCASTLE   (Australia)

^f NANYANG TECHNOLOGICAL UNIVERSITY   (Singapore)

^g MINISTRY OF HEALTH   (Singapore)

^h UNIVERSITY OF SYDNEY   (Australia)

ⁱ PATHWEST LABORATORY MEDICINE   (Australia)

^j UNIVERSITY OF WESTERN AUSTRALIA   (Australia)

^k CHILDREN S HOSPITAL AT WESTMEAD   (Australia)

^l QUEEN MARY UNIVERSITY OF LONDON   (United Kingdom)

more..

Author keywords

[No Author keywords available]

Indexed keywords

ADAMANTANE; INACTIVATED VACCINE; INFLUENZA VACCINE; OSELTAMIVIR; SIALIDASE;

ADULT; AMINO ACID SUBSTITUTION; ANTIVIRAL RESISTANCE; ARTICLE; ASIA PACIFIC; AUSTRALIA; CLINICAL ARTICLE; COMMUNITY; EASTERN HEMISPHERE; EPIDEMIOLOGICAL DATA; FEMALE; GENE CLUSTER; GENERAL PRACTICE; GENETIC SIMILARITY; HOSPITAL; HUMAN; INFANT; INFLUENZA A (H1N1); INFLUENZA VIRUS A H1N1; INFLUENZA VIRUS A H1N1 PDM09; MALE; MATHEMATICAL ANALYSIS; NONHUMAN; PRIORITY JOURNAL; SENTINEL SURVEILLANCE; VIRUS MUTANT; VIRUS MUTATION; VIRUS RESISTANCE; VIRUS STRAIN; VIRUS TRANSMISSION;

ADOLESCENT; ADULT; ANTIVIRAL AGENTS; AUSTRALIA; BASE SEQUENCE; CHILD; CHILD, PRESCHOOL; COMMUNITY-ACQUIRED INFECTIONS; DISEASE OUTBREAKS; DNA, VIRAL; DRUG RESISTANCE, VIRAL; FEMALE; HUMANS; INFANT; INFLUENZA A VIRUS, H1N1 SUBTYPE; INFLUENZA, HUMAN; MALE; MIDDLE AGED; MOLECULAR SEQUENCE DATA; MUTATION; NEURAMINIDASE; OSELTAMIVIR; PHYLOGENY; SEQUENCE ALIGNMENT; YOUNG ADULT;

EID: 84862902952     PISSN: 00221899     EISSN: None     Source Type: Journal    
DOI: 10.1093/infdis/jis337     Document Type: Article

References (42)

1. Farias JA, Fernandez A, Monteverde E, et al. Critically ill infants and children with influenza A (H1N1) in pediatric intensive care units in Argentina. Intensive Care Med 2010; 36:1015-22.
2. Creanga AA, Johnson TF, Graitcer SB, et al. Severity of 2009 pandemic influenza A (H1N1) virus infection in pregnant women. Obstet Gynecol 2010; 115:717-26.
3. Ling LM, Chow AL, Lye DC, et al. Effects of early oseltamivir therapy on viral shedding in 2009 pandemic influenza A (H1N1) virus infection. Clin Infect Dis 2010; 50:963-9.
4. Campbell CN, Mytton OT, McLean EM, et al. Hospitalization in two waves of pandemic influenza A(H1N1) in England. Epidemiol Infect 2010; 139:1560-9.
5. Newsome K, Williams J, Way S, et al. Maternal and Infant Outcomes Among Severely Ill Pregnant and Postpartum Women with 2009 Pandemic Influenza A (H1N1)-United States, April 2009-August 2010. MMWR Morb Mortal Wkly Rep 2011; 60:1193-6.
6. Khandaker G, Zurynski Y, Lester-Smith D, et al. Clinical features, oseltamivir treatment and outcome in infants aged <12 months with laboratory-confirmed influenza A in 2009. Antivir Ther 2011; 16: 1005-10
7. Graitcer SB, Gubareva L, Kamimoto L, et al. Characteristics of patients with oseltamivir-resistant pandemic (H1N1) 2009, United States. Emerg Infect Dis 2011; 17:255-7.
8. Hurt AC, Deng Y, Ernest J, et al. Oseltamivir-resistant influenza viruses circulating during the first year of the influenza A(H1N1)2009 pandemic in the Asia-Pacific region, March 2009 to March 2010. Euro Surveill 2011; 16:19770.
9. Meijer A, Jonges M, Abbink F, et al. Oseltamivir-resistant pandemic A (H1N1) 2009 influenza viruses detected through enhanced surveillance in the Netherlands, 2009-2010. Antiviral Res 2011; 92:81-9.
10. Gubareva LV, Kaiser L, Hayden FG. Influenza virus neuraminidase inhibitors. Lancet 2000; 355:827-35.
11. Meijer A, Lackenby A, Hungnes O, et al. Oseltamivir-resistant influenza virus A (H1N1), Europe, 2007-08 season. Emerg Infect Dis 2009; 15:552-60.
12. Hurt AC, Ernest J, Deng Y, et al. Emergence and spread of oseltamivir-resistant A(H1N1) influenza viruses in Oceania, South East Asia and South Africa. Antiviral Res 2009; 83:90-3.
13. Herlocher ML, Truscon R, Elias S, et al. Influenza viruses resistant to the antiviral drug oseltamivir: transmission studies in ferrets. J Infect Dis 2004; 190:1627-30.
14. Ives JAL, Carr JA, Mendel DB, et al. The H274Y mutation in the influenza A/H1N1 neuraminidase active site following oseltamivir phosphate treatment leave virus severely compromised both in vitro and in vivo. Antiviral Res 2002; 55:307-17.
15. Saito R, Sato I, Suzuki Y, et al. Reduced effectiveness of oseltamivir in children infected with oseltamivir-resistant influenza A (H1N1) viruses with His275Tyr mutation. Pediatr Infect Dis J 2010; 29:898-904.
16. Kawai N, Ikematsu H, Iwaki N, et al. Clinical effectiveness of oseltamivir for influenza A(H1N1) virus with H274Y neuraminidase mutation. J Infect 2009; 59:207-12.
17. Matsuzaki Y, Mizuta K, Aoki Y, et al. A two-year survey of the oseltamivir-resistant influenza A(H1N1) virus in Yamagata, Japan and the clinical effectiveness of oseltamivir and zanamivir. Virol J 2010; 7:53.
18. Kawai N, Ikematsu H, Hirotsu N, et al. Clinical effectiveness of oseltamivir and zanamivir for treatment of influenza A virus subtype H1N1 with the H274Y mutation: a Japanese, multicenter study of the 2007-2008 and 2008-2009 influenza seasons. Clin Infect Dis 2009; 49:1828-35.
19. Wolfe C, Greenwald I, Chen L. Pandemic (H1N1) 2009 and oseltamivir resistance in hematology/oncology patients. Emerg Infect Dis 2010; 16:1809-11.
20. Moore C, Galiano M, Lackenby A, et al. Evidence of person-to-person transmission of oseltamivir-resistant pandemic influenza A(H1N1) 2009 virus in a hematology unit. J Infect Dis 2011; 203:18-24.
21. Chen LF, Dailey NJ, Rao AK, et al. Cluster of oseltamivir-resistant 2009 pandemic influenza A (H1N1) virus infections on a hospital ward among immunocompromised patients-North Carolina, 2009. J Infect Dis 2011; 203:838-46.
22. Oseltamivir-resistant 2009 pandemic influenza A (H1N1) virus infection in two summer campers receiving prophylaxis-North Carolina 2009. MMWR Morb Mortal Wkly Rep 2009; 58:969-72.
23. Le QM, Wertheim HF, Tran ND, et al. A community cluster of oseltamivir-resistant cases of 2009 H1N1 influenza. N Engl J Med 2010; 362:86-7.
24. Lackenby A, Moran GJ, Pebody R, et al. Continued emergence and changing epidemiology of oseltamivir-resistant influenza A(H1N1) 2009 virus, United Kingdom, winter 2010/11. Euro Surveill 2011; 16:19784.
25. WHO Global Influenza Surveillance and Response System. Summary of influenza antiviral susceptibility surveillance findings, September 2010-March 2011. http://www.who.int/influenza/gisrs
26. Hurt AC, Hardie K, Wilson NJ, et al. Community transmission of oseltamivir-resistant A(H1N1)pdm09 influenza. N Engl J Med 2011; 365:2541-2.
27. WHO Global Influenza Surveillance Network. Manual for the laboratory diagnosis and virological surveillance of influenza. http://whqlibdoc.who.int/ publications/2011/9789241548090-eng.pdf. Access ed 7 December 2011.
28. Hurt AC, Barr IG, Hartel G, et al. Susceptibility of human influenza viruses from Australasia and South East Asia to the neuraminidase inhibitors zanamivir and oseltamivir. Antiviral Res 2004; 62: 37-45.
29. Deng YM, Caldwell N, Hurt A, et al. A comparison of pyrosequencing and neuraminidase inhibition assays for the detection of oseltamivirresistant pandemic influenza A(H1N1) 2009 viruses. Antiviral Res 2011; 90:87-91.
30. Wu WL, Lau SY, Chen Y, et al. The 2008-2009 H1N1 influenza virus exhibits reduced susceptibility to antibody inhibition: Implications for the prevalence of oseltamivir resistant variant viruses. Antiviral Res 2012; 93:144-53.
31. Hurt AC, Holien JK, Parker M, et al. Oseltamivir resistance and the H274Y neuraminidase mutation in seasonal, pandemic and highly pathogenic influenza viruses. Drugs 2009; 69:2523-31.
32. Bloom JD, Nayak JS, Baltimore D. A computational-experimental approach identifies mutations that enhance surface expression of an oseltamivir-resistant influenza neuraminidase. PLoS ONE 2011; 6: e22201.
33. Bloom JD, Gong LI, Baltimore D. Permissive secondary mutations enable the evolution of influenza oseltamivir resistance. Science 2010; 328:1272-5.
34. Gubareva L, Nguyen HT, Sleeman K, et al. Comprehensive assessment of the drug susceptibility of 2009 H1N1 influenza viruses [abstract O-821]. In: Program and abstracts of the International Society for Influenza and other Respiratory Virus Diseases: Options for the Control of Influenza VII, 2010:18.
35. Sheu TG, Deyde VM, Okomo-Adhiambo M, et al. Surveillance for neuraminidase inhibitor resistance among human influenza A and B viruses circulating worldwide from 2004 to 2008. Antimicrob Agents Chemother 2008; 52:3284-92.
36. Oo C, Barrett J, Hill G, et al. Pharmacokinetics and dosage recommendations for an oseltamivir oral suspension for the treatment of influenza in children. Paediatr Drugs 2001; 3:229-36.
37. Memoli MJ, Hrabal RJ, Hassantoufighi A, et al. Rapid selection of oseltamivir-and peramivir-resistant pandemic H1N1 virus during therapy in 2 immunocompromised hosts. Clin Infect Dis 2010; 50:1252-5.
38. WHO. WHO guidelines for pharmacological management of pandemic influenza A(H1N1) 2009 and other influenza viruses. Revised February 2010. http://www.who.int/csr/resources/publications/swineflu/h1n1-guidelines- pharmaceutical-mngt.pdf. Accessed 7 December 2011.
39. Abed Y, Boivin G, Yoshida R, et al. Parenteral peramivir treatment for oseltamivir-resistant 2009 pandemic influenza A H1N1 viruses. J Infect Dis 2011; 204:1641-2.
40. Storms AD, Gubareva LV, Su ST, et al. Oseltamivir-resistant pandemic (H1N1) 2009 virus infections, United States, 2010-11. Emerg Infect Dis 2012; 18:308-11.
41. Bao Y, Bolotov P, Dernovoy D, et al. The influenza virus resource at the National Center for Biotechnology Information. J Virol 2008; 82:596-601.
42. Katoh K, Toh H. Recent developments in the MAFFT multiple sequence alignment program. Brief Bioinform 2008; 9:286-98.